Vimarsana
Biggest News Aggregation in the World

Page 4 - Prospective Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prospective Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prospective Study Today - Breaking & Trending Today

Artificial heart maker Carmat announces progress on its Aeson device - Vimarsana News

Artificial heart maker Carmat announces progress on its Aeson device

PARIS (Reuters) -French artificial heart maker Carmat said on Monday it had implanted seven of its Aeson devices as part of a clinical study in Paris, sending its shares up almost 8%. “This ramp-up is the result of growing experience in patient selection and attests to the steep learning curve of the surgical procedure,” Professor Christian Latremouille, director of surgical affairs at Carmat, said in a press release. The clinical study, called EFICAS, is a prospective study designed to include 52 patients eligible for transplants, currently enrolled by a network of six French...

Source: yahoo.com
CARMAT Presented Its Progress on the EFICAS Clinical Study at the 36th Journées de La Pitié in Paris - Vimarsana News

CARMAT Presented Its Progress on the EFICAS Clinical Study at the 36th Journées de La Pitié in Paris

PARIS, October 23, 2023--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), announces that it has presented its progress on the EFICAS clinical trial at the 36th "Journées de La Pitié" national conference on heart and lung transplantation and circulatory assistance, organized by the cardi

Source: yahoo.com
Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening - Vimarsana News

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is spearheading a transformative change in breast cancer screening, bolstered by groundbreaking findings from a prospective study led by Dr. Fredrik Strand at the Karolinska Institutet, Sweden, involving over 50,000 women.

Source: yahoo.com
EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome - Vimarsana News

EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome

NeurAxis Inc (NYSE: NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research. The publication investigated changes in gastrointestinal symptoms and quality of life in 31 adolescent patients aged 11 – 18 years with functional abdominal pain disorders (FAPDs) before and after treatment with IB-Stim. Also Read: EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy

Source: yahoo.com
EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids - Neuraxis (AMEX:NRXS) - Vimarsana News

EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids - Neuraxis (AMEX:NRXS)

NeurAxis Inc (NYSE: NRXS) highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-conc